Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma
Autor: | Vikas Gupta, Jeffrey H. Lipton, Hans A. Messner, Gregory R. Pond, Richard W. Tsang, John Kuruvilla |
---|---|
Rok vydání: | 2008 |
Předmět: |
Oncology
Adult Male medicine.medical_specialty Transplantation Conditioning Follicular lymphoma Transplantation Autologous Disease-Free Survival Breast cancer Unrelated Donor Internal medicine Follicular phase medicine Overall survival Humans Lymphoma Follicular Retrospective Studies Salvage Therapy Transplantation Myeloablative business.industry Graft vs Tumor Effect Remission Induction Age Factors Hematology Middle Aged medicine.disease Confidence interval Surgery Allogeneic stem cell transplantation Female Stem cell Neoplasm Recurrence Local business Follow-Up Studies Stem Cell Transplantation |
Zdroj: | Biology of Blood and Marrow Transplantation. 14(7):775-782 |
ISSN: | 1083-8791 |
DOI: | 10.1016/j.bbmt.2008.04.007 |
Popis: | Allogeneic stem cell transplantation (Allo-SCT) remains an option for patients with follicular lymphoma (FL). We performed a retrospective analysis to examine long-term disease control and treatment-related mortality (TRM) in a group of patients that underwent transplant for clinically high-risk disease. Thirty-seven patients with indolent FL (follicular small cleaved [FSC], follicular mixed [FM] or FL grades 1 or 2 by WHO criteria) underwent allo-SCT. Patients were in a chemosensitive remission at the time of SCT. The conditioning regimen was typically busulfan-cyclophosphamide (BuCy). Cyclophosphamide-total body irradiation (TBI) was used for unrelated donor SCT. The median age at the time of transplant was 45 years (range: 24-58). The median number of prior chemotherapy regimens was 3 (range: 1-6). Thirty-seven patients received BuCy conditioning and 2 patients underwent reduced intensity conditioning SCT. Seventy-two percent of patients had a matched sibling donor. With a median follow-up of 63.5 months in survivors, the 5-year overall survival is 79.1% (95% confidence interval 66.3%-94.4%). TRM was 15.4%, with an additional case of mortality from breast cancer. These results demonstrate that in selected younger patients, a fully myeloablative allo-SCT utilizing BuCy conditioning provides excellent OS and disease control with low TRM. |
Databáze: | OpenAIRE |
Externí odkaz: |